Phase 2, randomized, double-blind trial (NCT01120119) evaluating calcitriol in preserving beta cell function in recent-onset T1D. Primary outcome measures include changes in fasting and stimulated C-peptide, insulin requirements and HbA1c. Participants are followed up for 24 months (67). The gene discussed is INS; the disease is type 1 diabetes mellitus.